Clinical Trial Update: Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung Disease [Phase 3]

View source ↗

Summary

Phase 3 clinical trial assessing efficacy and safety of pirfenidone in systemic sclerosis-associated interstitial lung disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis-associated Interstitial Lung Disease

Drugs mentioned

• PIRFENIDONE (pirfenidone)

Snippet

Sponsor: Beijing Continent Pharmaceutical Co, Ltd. | Conditions: Systemic Sclerosis-associated Interstitial Lung Disease (Ssc-ild) | Phase 3 | Status: UNKNOWN